DURECT is a biopharmaceutical company actively developing new therapeutics based on its Epigenomic Regulator Program and proprietary drug delivery platforms. DUR-928, a new chemical entity in Phase 1 development, is the lead candidate in DURECT’s Epigenomic Regulator Program. An endogenous, orally bioavailable small molecule, DUR-928 plays an important regulatory role in lipid homeostasis, inflammation, and cell survival, and may have applications related to acute organ injury and chronic metabolic disease, notably nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). DURECT’s advanced oral, injectable, and transdermal delivery technologies enable new indications and enhanced attributes, such as abuse deterrence, extended dosing intervals, and superior safety and efficacy, for small-molecule and biologic drugs. Late-stage development programs in this category include POSIMIR® and REMOXY®, addressing key unmet needs in pain management.

Stock Quote
NASDAQ DRRX (Common Stock)
Oct 21, 2016 3:46 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent News | View All >
DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII

Read More

DURECT to Present at the Rodman & Renshaw Global Investment Conference

Read More

Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever DURECT Corporation posts new information to the site. Just enter your e-mail address and click Submit.
Transfer Agent
Computershare Trust Company N.A.
250 Royall Street, Mailstop 3B
Canton, MA 02021
Phone: 781-575-3400

Ernst & Young LLP
1001 Page Mill Road
Palo Alto, CA 94304
Phone: 650-496-1600
Fax: 650-496-1600